期刊文献+

低中危组急性早幼粒细胞白血病患者双诱导治疗后加入细胞毒性药物时机的早期临床分析研究 被引量:1

Early Clinical Investigation on Timing of Addition of Cytotoxic Drugs after Dual Induction Treatment in Patients with Acute Promyelocytic Leukemia in Low-and Medium-risk Groups
下载PDF
导出
摘要 目的比较低中危组急性早幼粒细胞白血病(APL)患者进行双诱导治疗后,在不同外周血白细胞计数(WBC)时予以细胞毒性药物的疗效和不良反应。方法选取2011年3月—2017年4月重庆医科大学附属第一医院收治的初诊APL患者36例,对其进行全反式维甲酸(ATRA)+三氧化二砷(ATO)双诱导治疗。根据加入细胞毒性药物时外周血WBC,以不同的标准对患者进行分组:(1)(10~20)×10~9/L组和>20×10~9/L组;(2)(10~25)×10~9/L组和>25×10~9/L组;(3)(10~30)×10~9/L组和>30×10~9/L组。分析各组患者完全缓解(CR)率、达CR所需时间、凝血功能异常持续时间,以及诱导期间的不良反应发生情况。结果 36例患者诱导期间无一例死亡。(10~20)×10~9/L组达CR所需时间短于>20×10~9/L组(P<0.05);(10~20)×10~9/L组和>20×10~9/L组CR率、凝血功能异常持续时间比较,差异均无统计学意义(P>0.05)。(10~25)×10~9/L组和>25×10~9/L组、(10~30)×10~9/L组和>30×10~9/L组CR率、达CR所需时间、凝血功能异常持续时间比较,差异均无统计学意义(P>0.05)。(10~20)×10~9/L组、(10~25)×10~9/L组、(10~30)×10~9/L组平均WBC峰值分别低于>20×10~9/L组、>25×10~9/L组、>30×10~9/L组(P<0.05);(10~20)×10~9/L组和>20×10~9/L组、(10~25)×10~9/L组和>25×10~9/L组、(10~30)×10~9/L组和>30×10~9/L组分化综合征(DS)发生率、感染发生率、肝功异常率、3~4级骨髓抑制发生率比较,差异均无统计学意义(P>0.05)。结论低中危组APL患者进行ATRA-ATO双诱导治疗后,外周血WBC在(10~20)×10~9/L时加用细胞毒性药物可获得相对较佳的早期疗效。 Objective After induction therapy in patients with acute promyelocytic leukemia(APL)at a low-tointermediate risk level,the efficacy and adverse reactions of cytotoxic drugs vary at different WBC levels.Methods Thirty-six patients with newly diagnosed APL admitted to the First Affiliated Hospital of Chongqing Medical University from March 2011 to April 2017 were enrolled and received dual induction therapy of all trans-retinoic acid and arsenic trioxide.With different standards,patients were divided into three groups according to WBCs:(1)(10-20)×109/L group and>20×109/L group;(2)(10-25)×109/L group and>25×109/L group;and(3)(10-30)×109/L group and>30×109/L group.The rate of complete remission(CR),the time required to reach CR,the duration of coagulation dysfunction,and the adverse reactions during the induction period were analyzed in these groups.Results None of the 36 patients died during induction.In the WBC(10-20)×109/L group,the time required for CR was shorter than the time required in the WBC>20×109/L group(P<0.05);however,there was no statistical difference in the CR rate and the duration of coagulation dysfunction between the(10-20)×109/L group and>20×109/L group(P>0.05).No statistical differences were observed in the CR rate,the time required for CR,and the duration of coagulation dysfunction in the(10-25)×109/L,>25×109/L,(10-30)×109/L,and>30×109/L groups(P>0.05).The average WBC peak in the(10-20)×109/L,(10-25)×109/L,and(10-30)×109/L groups was lower than the>20×109/L,>25×109/L,and>30×109/L groups,respectively.There was no statistical difference regarding the incidence of differentiation syndrome,infections,abnormal liver function,and grade 3-4 myelosuppression among the(10-20)×109/L,>20×109/L groups,and the(10-25)×109/L,>25×109/L,(10-30)×109/L,and>30×109/L groups(P>0.05).Conclusion After ATO-ATRA double-induction therapy in APL patients in the low-intermediate risk groups,cytotoxic drugs with a WBC of(10-20)×109/L in the peripheral blood achieved a relatively good early curativ
作者 李连文 刘北忠 陈建斌 姚仕菲 陈敏 赵毅 刘路 钟梁 LI Lian-wen;LIU Bei-zhong;CHEN Jianbin;YAO Shi-fei;CHEN Min;ZHAO Yi;LIU Lu;ZHONG Liang(Yongchuan Hospital,Chongqing Medical University,Chongqing 402160,China;Key Laboratory of Laboratory Medical Diagnostics,Ministry of Education,Faculty of Laboratory Medical,Chongqing Medical University,Chongqing 400016,China;Department of Hematology,the First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)
出处 《中国全科医学》 CAS 北大核心 2018年第8期924-928,共5页 Chinese General Practice
基金 国家自然科学基金面上资助项目(81772280) 重庆市自然科学基金重点项目(2011BA5037)
关键词 白血病 早幼粒细胞 急性 药物毒性 治疗时机 诱导治疗 ukemia,promyelocytic,acute Drug toxicity Timing of initiating chemotherapy Induction therapy
  • 相关文献

参考文献5

二级参考文献1

共引文献103

同被引文献9

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部